Piper Sandler Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $24
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $24.
Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $24.